Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

• Status: Active, not recruiting
• Trial end date: 2023-01-01

Summary

This study will compare DS-8201a to physician choice standard treatment.

Participants must have HER2-low breast cancer that has been treated before.

Participants' cancer:

• Cannot be removed by an operation

• Has spread to other parts of the body

• Phase: Phase 3

Details

• Lead Sponsor: Daiichi Sankyo, Inc.
• Collaborators: AstraZeneca; Daiichi Sankyo Co., Ltd.
• Treatments: Albumin-Bound Paclitaxel; Antineoplastic Agents; Camptothecin; Capecitabine; Gemcitabine; Immunoconjugates; Paclitaxel; Trastuzumab